levofloxacin tablet, film coated
proficient rx - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr
cyclen tablets (28 day)
janssen inc - norgestimate; ethinyl estradiol - tablet - 0.25mg; 0.035mg - norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives
cyclen tablets (21 day)
janssen inc - norgestimate; ethinyl estradiol - tablet - 0.25mg; 0.035mg - norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives
tri-cyclen tablets - 21-day
janssen inc - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol - tablet - 0.18mg; 0.035mg; 0.215mg; 0.035mg; 0.25mg; 0.035mg - norgestimate 0.18mg; ethinyl estradiol 0.035mg; norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives
tri-cyclen tablets - 28-day
janssen inc - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; ethinyl estradiol; norgestimate - tablet - 0.215mg; 0.035mg; 0.25mg; 0.035mg; 0.035mg; 0.18mg - norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg; ethinyl estradiol 0.035mg; norgestimate 0.18mg - contraceptives
ntp-doxycycline tablets
teva canada limited - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines
doxycycline tablets
sanis health inc - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines
levofloxacin tablet, film coated
direct rx - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mi
levofloxacin tablet, film coated
proficient rx lp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tabletsshould be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr
levofloxacin tablet, film coated
blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see microbiology (12.4